Nuclear receptors and Signal transduction
Introduction:
Statins are drugs used for the treatment of hypercholesterolemia. Statins have two chiral centers in their molecules, thus they form four enantiomers:3R5R-, 3R5S-, 3S5R-and 3S5S-. Regarding the most frequently prescribed statins, following enantiopure formulations are used in the clinics: 3R5R-atorvastatin, 3R5S-rosuvastatin and 3R5S-fluvastatin (Figure 1 ). Individual enantiomers of one drug can qualitatively and quantitatively differ in their biological activities. In some cases, only one enantiomer is responsible for the therapeutic effect, while the opposite one may be inactive or can cause undesired or even toxic effects. Therefore, it is of value to study in vitro effects of individual enantiomers. We investigated enantiospecific interactions of four enantiopure forms of atorvastin, rosuvastatin and fluvastatin with main transcriptional regulators of drug-metabolizing enzymes -aryl hydrocarbon receptor (AhR) (data not shown), glucocorticoid receptor (GR) (data not shown) and pregnane X receptor (PXR). Agonist and antagonist activities of tested compounds towards AhR, PXR and GR were determined using human reporter cell lines. Moreover, we have measured expression of drug-metabolizing enzymes CYPs on mRNA and protein level in primary human hepatocytes.
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Conclusion:
We have investigated enantioselective effects of statins on the expression of xenobioticmetabolizing human enzymes. The data showed that the potential for drug-drug interactions involving induction of P450s is higher for clinically used optical isomers of rosuvastatin, atorvastatin and fluvastatin, as compared to their respective enantiomers, which are not in therapeutic use. 
Effects of statin enantiomers on the expression of drug-metabolizing cytochromes P450 in primary human hepatocytes
We examined a capability of statin enantiomers to induce transcriptionally regulated drugmetabolizing cytochromes P450 in three human hepatocytes cultures (HH59, HH61, HH63). Hepatocytes were treated for 24 h (for determination of mRNA) or 48 h (for determination of proteins) with optical isomers of tested statins (1 μM, 10 μM, 30 μM), rifampicin (RIF; 10 μM) and vehicle (DMSO; 0.1% v/v). Measurements were performed in triplicates. Gene expression was normalized to GAPDH as a housekeeping gene. The expression of CYP1A1 and CYP1A2 in human hepatocytes was not influenced by tested statins. All statins induced CYP2A6, CYP2B6 and CYP3A4, and the effects on CYP2C9 were rather modulatory. The effects varied between statins and enantiomers and induction potency decreased in order: atorvastatin (RR>RS=SR>SS)  fluvastatin (SR>RS=SS>RR)  rosuvastatin (only RS active). 
Binding of PXR to DNA -electrophoretic mobility shift assay
We tested whether the effects of statins on PXR-CYP3A4 signaling pathway involves also changes in the formation of PXR/RXRα-DNA complex. PXR-mediated gene activation requires direct binding of the PXR-RXRa heterodimeric complex to the response elements in the gene promoter. Maximal induction of CYP3A4 gene expression apparently requires an additional DR3 nuclear receptor-binding element 1(dNR1; -7733/-7719) in a distal xenobiotic responsive enhancer module 2,3 . Nuclear extracts from LS174T cells treated by DMSO (0.1% v/v), RIF (10 μM) and individual enantiomers of atorvastatin, rosuvastatin and fluvastatin at concentration 10 μM were incubated with biotin-labeled double-stranded oligonucleotide corresponding to the DR3 PXR response element in the CYP3A4 promoter and resolved on non-denaturing gel. The specificity of PXR-RXRa binding was confirmed by competition with non-labeled double-stranded DR3 oligonucleotide. Positive control RIF strongly stimulated a formation of PXR/RXRα-DNA-binding complex. All tested compouds increased binding of PXR/RXRa to the DR3 module in comparison with vehicle ( Figure 4A ). Immunoblot analysis confirmed that equal amounts of PXR proteins were used in the gel shift assay ( Figure 4B ).
